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Abstract
Background: Genome-wide association studies (GWASs) have identified a large number of variants (SNPs) associating with
an increased risk of coronary artery disease (CAD). Recently, the CARDIoGRAM consortium published a GWAS based on the
largest study population so far. They successfully replicated twelve already known associations and discovered thirteen new
SNPs associating with CAD. We examined whether the genetic profiling of these variants improves prediction of subclinical
atherosclerosis – i.e., carotid intima-media thickness (CIMT) and carotid artery elasticity (CAE) – beyond classical risk factors.
Subjects and Methods:We genotyped 24 variants found in a population of European ancestry and measured CIMT and CAE
in 2001 and 2007 from 2,081, and 2,015 subjects (aged 30–45 years in 2007) respectively, participating in the Cardiovascular
Risk in Young Finns Study (YFS). The Bogalusa Heart Study (BHS; n = 1179) was used as a replication cohort (mean age of
37.5). For additional replication, a sub-sample of 5 SNPs was genotyped for 1,291 individuals aged 46–76 years participating
in the Health 2000 population survey. We tested the impact of genetic risk score (GRS24SNP/CAD) calculated as a weighted (by
allelic odds ratios for CAD) sum of CAD risk alleles from the studied 24 variants on CIMT, CAE, the incidence of carotid
atherosclerosis and the progression of CIMT and CAE during a 6-year follow-up.
Results: CIMT or CAE did not significantly associate with GRS24SNP/CAD before or after adjusting for classical CAD risk factors
(p.0.05 for all) in YFS or in the BHS. CIMT and CAE associated with only one SNP each in the YFS. The findings were not
replicated in the replication cohorts. In the meta-analysis CIMT or CAE did not associate with any of the SNPs.
Conclusion: Genetic profiling, by using known CAD risk variants, should not improve risk stratification for subclinical
atherosclerosis beyond conventional risk factors among healthy young adults.
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Introduction
Current risk assessment strategies do not fully explain the factors
underlying cardiovascular risk [1]. Emphasizing this, risk scores
based on serum lipid levels and traditional factors such as smoking,
hypertension, sex, etc., lack accuracy in risk prediction and have a
tendency to overestimate the risk in low-risk populations and to
underestimate the risk in high-risk populations [2]. The role of the
hereditary component in the development of atherosclerosis
should be studied further as the progression of the disease is also
influenced by genetics. This could lead to improved risk
assessment strategies.
The recent surge in genetic profiling with the aid of genome-
wide association studies (GWASs) has found novel variants
associating with myocardial infarction (MI) and coronary artery
disease (CAD) [3,4,5,6,7,8,9,10]. These variants could be
biomarkers themselves or point to circulating markers for further
exploration [11]. The most recent GWAS-based meta-analysis (the
CARDIoGRAM consortium), with the largest population sample
to date (,22,000 cases and ,65,000 controls with a replication
sample of ,57,000 individuals), revealed 13 new genome-wide -
significant candidate loci associating with the occurrence of CAD
and successfully replicated twelve previously discovered associa-
tions [3,4,5,6,7,8,9,10,12]. Although these CAD variants strongly
associate with the risk of CAD, their potential role in the
development of atherosclerosis is still obscure.
Atherosclerosis begins with a subclinical phase starting in
childhood and young adulthood [13,14]. Although it is the first
stage of the disease, mainly manifested by an early intimal
thickening and decreased elasticity of the arteries, it may be used
to predict the future outcome of the disease. Increased subclinical
atherosclerosis, as assessed by carotid artery intima-media
thickness (CIMT) or elasticity (CAE), is a strong predictor of
future cardiovascular events such as MI and stroke [2,5,8]. For this
reason, the identification of individuals at high hereditary
subclinical risk could be utilized in primary prevention
[15,16,17]. Furthermore, it would be very useful to clarify the
mechanisms by which these variants exert their effects on the risk
of CAD. At present, only five SNPs associated with CAD in
previous GWASs(rs10757274, rs1333049, rs6922269 rs501120
and rs2943634) have been investigated for possible associations
with subclinical atherosclerosis [18,19,20,21,22]. Of these five,
three variants are in complete or high linkage disequilibrium with
two of the risk variants for CAD identified by the CARDIoGRAM
consortium.
Given the current gap in knowledge, we tested the hypothesis
that genetic profiling by using these novel CAD variants could be
useful in the risk stratification for subclinical atherosclerosis
(depicted by CAE and CIMT) before and after adjusting for
traditional risk factors. Genetic information on these variants was
used to form a genetic risk score depicting individual risk for CAD
(GRSSNP/CAD). The possible effects of individual SNPs were also
screened. For these analyses we used three representative
population-based studies, i.e., The Cardiovascular Risk in Young
Finns and The Bogalusa Heart Study. A subsample of the SNPs
was also previously genotyped from the Health 2000 Survey
cohort and the results were used for further replication.
Results
General characteristics of the study populations
In 2007, the mean age of the YFS population was 37.5 years (S.D.
5.0). There were 2,015 subjects with both ultrasound and
genotyping data available. One of the subjects had established
cardiovascular disease, 43 were on antihypertensive medication,
and 7 (0.3%) were on lipid-lowering medication. The use of lipid
medication was more frequent in the replication cohorts: 68 (5.8%)
in the Bogalusa Heart Study and 128 (9.2%) in the Health 2000
survey. The general characteristics of the YFS population and
replication cohorts are presented in Table 1. All of the 24 genotypes
followed the Hardy-Weinberg equilibrium (p.0.05 for x2 -test).
The association between GRS24SNP/CAD and subclinical
atherosclerosis in the YFS
According to both unadjusted and adjusted linear regression
analyses the GRS24SNP/CAD did not associate with CIMT
measured in 2007 and 2001 or with the 6-year incidence of high
carotid atherosclerosis (Table 2 and Figure 1). The GRS24SNP/CAD
had no age-, sex- or BMI-dependent associations with CIMT
(p = 0.327 for age-by-risk score interaction, p = 0.522 for sex-by-
risk score interaction and p = 0.454 for BMI-by-risk score
interaction). The progression of CIMT between 2001 and 2007
was also unaffected by the GRS24SNP/CAD (Figure 1). Figure 1
demonstrates the mean CIMT values measured in 2001 and 2007
for each quartile when the study population was stratified
according to risk allele dosage.
Similarly, the GRS24SNP/CAD did not associate with carotid
artery elasticity measured in 2007 although a borderline
association was seen before adjusting the analysis with age, sex
and BMI. Before any adjustments, a change of one standard
deviation in the risk score seemed to associate with a lower
elasticity (a 20.00914% change [S.E. of 0.00496] in the lumen
diameter in response to a 10 mmHg increase in arterial blood
CAD Risk Variants and Sub-Clinical Atherosclerosis
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pressure, p = 0.065). However, this observed difference diminished
when age sex and BMI were added to the model
(b=20.00646%/10 mmHg with S.E. of 0.00459%/10 mmHg,
p = 0.160). In comparison, in the same model, male sex
corresponded to a 0.25014% decrease in elasticity in response to
a 10 mmHg change in arterial blood pressure (S.E. of 0.02906,
p = 1.5E217). The GRS24SNP/CAD was not observed to have any
major age-, sex- or BMI-dependent effects on CAE (p = 0.151 for
Table 2. The association between sub-clinical atherosclerosis measured from the carotid artery and the genetic risk score formed
from 24 risk variants previously associated with coronary artery disease.
Phenotype Beta* S.E. P-value
Intima Media Thickness
(mm)
Model 1 20.000015 0.00069 0.982
Model 2 20.00025 0.00063 0.694
Model 3a 20.00036 0.00063 0.574
Elasticity
(%/10 mmHg)
Model 1 20.00914 0.00496 0.065
Model 2 20.00646 0.00459 0.160
Model3b 20.0038 0.0045 0.397
OR** 95% CI P
6-year incidence of carotid
atherosclerosis***
Model 1 0.995 0.942 to 1.051 0.859
Model 2 1.000 0.945 to 1.058 0.997
Model 3a 0.998 0.941 to 1.057 0.936
Adjustments: Model 1 – unadjusted; Model 2 – age, sex and Body Mass Index; Model 3a – age, sex, body mass index, apoliprotein A, apolipoprotein B, systolic blood
pressure and waist circumference; Model 3b – age, sex, body mass index, blood glucose, waist circumference and diastolic blood pressure.
*Beta for a change of one standard deviation in the risk score.
**For an increase of one risk allele in the GRS24SNP/CAD.
***The 6-year incidence of carotid atherosclerosis is defined as the occurrence of substantial CIMT (age-, sex- and BMI- adjusted CIMT- value over 90% percentile) or
plaque in 2007 in subjects who did not have substantial CIMT or plaque in 2001.
Abbreviations: S.E., Standard Error; OR, Odds Ratio; CI, Confidence interval.
doi:10.1371/journal.pone.0028931.t002
Table 1. General characteristics of the three study populations with available ultrasound and genotype data.
Young Finns Study Health 2000 Survey The Bogalusa Heart Study
Men Women Men Women Men Women
n=909 n=1106 n=625 n=761 n=499 n=681
Age, years 37.5 (5.0) 37.5 (5.0) 58.0 (7.9) 58.6 (8.3) 37.8 (4.6) 37.3 (4.7)
BMI, kg/m2 26.7 (4.2) 25.4 (4.1) 27.5 (4.0) 27.1 (4.9) 29.9 (6.5) 30.0 (8.1)
Total Cholesterol, mmol/L 5.19 (0.95) 4.93 (0.86) 5.51 (0.92) 5.67 (0.92) 5.09 (1.13) 4.90 (0.96)
Triglycerides mmol/L 1.65 (1.13) 1.19 (0.66) 1.47 (0.84) 1.26 (0.64) 1.82 (1.43) 1.29.(076)
HDL-Cholesterol, mmol/L 1.21 (0.28) 1.44 (0.33) 1.43 (0.38) 1.71 (0.43) 1.13 (0.31) 1.34 (0.33)
LDL-Cholesterol, mmol/L 3.28 (0.82) 2.95 (0.73) 3.47 (0.88) 3.39 (0.85) 3.37 (1.00) 3.15 (0.87)
Systolic BP, mmHg 136.2 (13.1) 124.3 (13.9) 141.1 (20.5) 136.1 (22.4) 121.2 (14.0) 114.2 (14.6)
Diastolic BP, mmHg 84.8 (10.8) 80.2 (10.5) 87.3 (10.7) 84.0 (9.6) 81.7 (10.1) 77.0 (10.0)
CIMT, mm 0.644 0.613 0.830 0.788 0.810 0.741
(0.106) (0.086) (0.193) (0.167) (0.184) (0.156)
CAE, diameter change 1.740 2.020 0.880 0.946 - -
(%)/10 mmHg (0.614) (0.729) (0.417) (0.522)
All units are expressed as mean (SD) except for dichotomous variables.
Abbreviations: CIMT, Carotid artery Intima Media Thickness; CAE Carotid Artery Elasticity; HDL, High Density Lipoprotein; LDL, Low Density Lipoprotein; BP, Blood
Pressure; BMI, body mass index.
doi:10.1371/journal.pone.0028931.t001
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age-by-risk score interaction, p = 0.090 for sex-by-risk score
interaction and p = 0.931 for BMI-by-risk score interaction).
Correspondingly, the GRS24SNP/CAD did not associate with
CAE in 2001 or with the progression of CAE between 2001 and
2007 (Figure 1).
When analysed separately, the individual SNPs did not have
any dramatic effect on CIMT or CAE measured in 2007. The
associations by all 24 genotypes are summarized in Table S1 and
Table S2. Only one SNP (rs4977574) was seen to associate
significantly with CIMT (p = 0.010) and only one variant
(rs4773144) associated significantly with CAE (p = 0.008). These
associations were not successfully replicated in any of the
replication cohorts (Tables S3, S4, and S5).
The performance of CAD SNPs in the prediction of
extreme CIMT in the YFS
Without any adjustments, the predictive value of the 24 SNPs
was not high (area under the receiver operating characteristic
curve [AUC] 0.604). Age, sex and BMI alone predicted extreme
CIMT better (AUC 0.831). Adding the few CAD SNPs with any
predictive effect on CIMT to the model did not seem to the
increase the prediction accuracy (AUC 0.838).
We have also showed previously that the group of SNPs with the
highest predictive value for extreme CIMT in the YFS population
in 2001 predicts extreme CIMT with an even greater accuracy in
2007 [23]. For this reason, we also whether there would be any
consistency in the results obtained in 2001 and 2007. According to
a machine learning –based SNP selection adjusted with age, sex
and BMI, the same CAD SNPs that were observed to provide
some predictive value for extreme CIMT in 2001 did not seem to
predict extreme CIMT in 2007 (Table S6).
Replication and the meta-analysis
In the Bogalusa Heart Study, genotype information was available
for 23 variants from a population of European ancestry and for 19
variants from a population of African ancestry. The genetic risk
score was formed accordingly from the available variants for both
populations separately. In line with the results of the YFS, the GRSs
thus formed did not associate with CIMT in the populations of
European or African ancestry. The analyses were repeated with no
adjustments and by adjusting for age, sex and BMI, in addition to
adjusting for serum lipid values (total cholesterol, LDL cholesterol,
HDL -cholesterol and triglycerides) and as well as systolic and
diastolic blood pressure, accepting only significant covariates into
the final model by a stepwise procedure (Table 3).
Only few of the SNPs associated individually with CIMT in the
separate replication cohorts and none associated in the meta-
analyses (Tables S3, S4, S5 and S7). None of the five genotyped
SNPs in the Health 2000 Survey associated with CAE (Table S3).
Discussion
We found that a genetic risk score formed of variants previously
associated with the risk of CAD on a genome-wide -significant
level (SNPs) does not predict the development of subclinical
atherosclerosis measured as intimal thickening, the arterial
elasticity of the carotid artery, or the incidence of high CIMT or
plaques during a six-year follow-up among healthy adults. The
results of the present study also showed that individual
polymorphisms do not have a substantial impact on the
development of subclinical atherosclerosis. The few observed
significant associations were moderate at best and were not
replicable. A meta-analysis of three independent study populations
confirmed the negative results.
CIMT is a good non-invasive method for evaluating the
development of atherosclerosis and it is associated with the risk of
CAD [24,25,26]. In apparently healthy young individuals, it
provides an excellent means to follow the development of the early
phases of atherosclerosis. A recent meta-analysis revealed that an
approximately 0.1 mm change in CIMT corresponds to an
increase of 15% in the risk of myocardial infarction [17]. In the
Figure 1. Subclinical atherosclerosis and the genetic predisposition to coronary artery disease (CAD). Carotid artery Intima Media
Thickness (CIMT) and Carotid Artery Elasticity (CAE) among healthy adults with different genetic risk for coronary artery disease (CAD). The study population
(The Cardiovascular risk in Young Finns Study) is stratified into four groups according to CAD risk allele dosage (calculated weighted risk score).
doi:10.1371/journal.pone.0028931.g001
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present study, the main cohort (YFS) alone had an 80% power to
detect at least 0.0155 mm changes for all SNPs in assuming
additive genotypic effects, which should therefore be enough to
reveal an at least 2.3% increase in the risk of MI. In the present
study, the genetic risk score did not associate with increased
CIMT. Previously, each of the studied 24 SNPs have been
associated with a 6%–29% increase in the risk of CAD per one risk
allele, depending on the variant [12]. In the YFS population, the
maximal significant difference in individual genotypic means was
0.013 mm, and it was not replicated in other cohorts.
Although similar GRSs have shown potential for being an
effective tool in risk stratification for CAD [27,28,29], the CAD
GRS used in the present study does not seem to have any
association with CIMT or CAE measured in a cross-sectional
study setting or with the development of these end-points in a six-
year follow-up. In the case of the GRS in the YFS, we achieved an
80% power to detect an at least 0.017 mm difference in CIMT
and a 0.120%/10 mmHg difference in CAE between the
individual population groups when the YFS population was
divided into four categories/quartiles by CAD risk score dosage.
The 0.017 mm difference in CIMT would correspond to a
maximum of 2.6% increase in the risk for MI (as discussed above).
As for CAE, the power of the current study was sufficient to detect
a difference of less than half (0.120%/10 mmHg) of the observed
difference between men and women in CAE (0.280%/10 mmHg)
when comparing any two quartiles. Considering our findings (or
the lack of significant associations), it is plausible to conclude that
the studied polymorphisms would have some other more powerful
ways of mediating the risk for CAD than through early intimal
thickening and decreased arterial elasticity, at least when
measured from the carotid artery among healthy adults. However,
the results of GRSs should be interpreted with caution especially
when only 24 variants are used to form a risk score. Thus far,
genetic risk scoring for Crohn’s disease, Bipolar disorder and even
CAD, has been shown effective in risk prediction, provided that a
sufficiently large amount (hundreds or even thousands) of variants
is used (even if their individual effects would be merely nominal)
[27,30,31]. We have previously shown in the YFS population that
it is possible to predict, with good accuracy, the risk for extreme
CIMT by using multiple SNPs of good predictive value even
though they would not associate statistically significantly with
CIMT. In fact, when combined with traditional risk factors, the
SNPs with high predictive value in a multivariate model (although
not statistically significantly associating with CIMT) predicted the
risk of extreme CIMT better (AUC of 0.844) than traditional risk
factors alone (AUC of 0.741). This method of comparing low and
high extremes of quantitative traits has been shown to provide
good statistical power for the studied variants [32,33,34]. In the
present study, the CAD SNPs did not seem to increase the
predictive value of the analysis when added to the model with age,
sex and BMI Supporting our conclusion, these CAD variants have
not been associated with CIMT or higher risk of carotid plaque in
a recent GWAS published during the preparation of the current
manuscript [35]. However, the application of the results of genetic
association studies and especially the use of genetic risk scores has
proved difficult in regard to most diseases with a complex etiology
[31]. Confounding factors such as different phenotypic diversity
within one disease group, as is the case with coronary heart
disease, gene–gene interactions and gene–environment interac-
tions as well as the modulating effect of time on genetic risk factors
are challenging.
Thus far only few studies have investigated the role of individual
SNPs associated with CAD in previous GWASs. The study by
Cunnington et al. failed to find any association between CIMT
and three individual CAD variants (rs1333049, rs6922269 and
rs2943634) [19]. These results are in line with the meta-analysis
results of the present study. We have also published a negative
result between the SNP rs1333049 and CIMT based on the earlier
measurements of the present YFS population from 2001 (at age
23–39 years) [21]. However, it is possible that some risk variants
with modest effect can only be discovered in older populations
with a heavier risk factor burden and more advanced CIMT
changes. This could explain the positive association (if not due to
chance) between CIMT and rs4977574 in 2007. The rs4977574 is
in high linkage disequilibrium with rs1333049 which in 2001 was
not observed to associate with CIMT. Supporting this, Ye et al.
have found rs1333049 to associate with CIMT among substan-
tially older subjects with a mean age of over 50- years. They also
found a positive connection between this variant and the
progression of CIMT during a 10- year follow-up [22].
At the time of the review process for the present publication,
another study was published with results supporting our findings.
The study by Conde et al. presented a meta-analysis of the
association between CIMT and eleven independent variants
previously associated with CAD in GWASs [36]. However, as
the meta-analysis also included the YFS population, the results of
the study by Conde et al. cannot be considered completely
independent of our current results. Although eight of the variants
overlap with the SNPs in the present publication, the SNP
selection of the present study is more extensive (based on the
Table 3. The association between carotid intima media thickness and genetic risk score (GRS) among two different study
populations of the Bogalusa Heart Study.
BHS European Ancestry (n=755) BHS African Ancestry (n =326)
Beta* S.E. P-value Beta* S.E. P-value
GRS
Model 1 20.00054 0.00198 0.785 0.00252 0.00455 0.580
Model 2 20.00246 0.00180 0.172 0.00344 0.00427 0.421
Model 3a/b 20.00277 0.00174 0.111 0.00346 0.00420 0.420
The GRS was calculated as a weighted sum of coronary artery disease risk alleles from 24 known variants.
Adjustments: Model 1 –unadjusted; Model 2 – age, sex and Body Mass Index; Model 3a (European ancestry) – age, sex, body mass index, total cholesterol, low density
lipoprotein -cholesterol, triglycerides and systolic blood pressure; Model 3b (African ancestry) – age, sex, body mass index, and systolic blood pressure. Abbreviations:
GRS, Genetic Risk Score, S.E., Standard Error.
*Change of CIMT in millimetres corresponding to a change of one standard deviation in the risk score.
doi:10.1371/journal.pone.0028931.t003
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results of the recent and thus far largest GWAS by the
CARDIoGRAM consortium). Furthermore, the current study
uniquely presents data from several measurements over time, thus
also enabling the investigation of the possible association between
individual variants associated with CAD on a genome-wide
significant level and the development of CIMT and CAE. No
other study has been published concerning the possible connection
between the development of subclinical atherosclerosis and an
extensive genetic risk score for CAD formed by using a similar
selection of SNPs.
In 2007 the present study population consisted of six age groups
between the ages of 30 and 45 years. As it is possible that with
increasing age the effect of hereditary risk factors could change, we
also screened for possible age-by-CAD risk score interactions
affecting CIMT and CAE. Although, the interaction analyses
showed no apparent age-dependent associations in the YFS or
BHS, the possibility that age would modulate the effect of the
individual genetic factors in older age groups or among
populations with a heavier atherosclerotic burden cannot be
excluded. A good example of this is the SNP rs501120 (locus
10q11.2) which is located upstream of the CXCL12 gene and is in
complete linkage disequilibrium with rs1746048 identified as a risk
variant for CAD by the CARDIoGRAM consortium [12]. In the
current study population of young adults, rs1746048 did not
associate significantly with CIMT or CAE. However,rs501120 and
rs1746048 did seem to associate with CIMT among the African
American population of the Bogalusa Heart Study as well as
among the study population of the Health 2000 Survey where only
rs501120 was genotyped. Both of these study populations have
higher mean CIMT values when compared to the study
population of the YFS orthe subjects of European ancestry in
the BHS. The possible confounding effect of genetic heterogeneity
can also explain some of the replication failures between these
samples. Furthermore, we have also shown in a larger meta-
analysis integrating three independent cohorts with a mean age
over 50- years (Bruneck, Health2000 and HTO), that rs501120
associates with CIMT. These separate cohorts are based on older
populations (Bruneck with an age range of 45–94 years,
Health2000 with an age range 46–76 years, and HTO with and
age range 19–88 years) [20].
The foremost problem of the present study is that we lacked
the replication data for some of the SNPs in the replication
cohorts, especially in the Health 2000 Survey. Therefore, we
were unable to evaluate the effect of the risk score on carotid
artery elasticity. However, we were able to replicate the findings
regarding CIMT for most of the variants, and the consistency of
the results obtained from each study population makes the
interpretation of the main results relatively safe. The main
strength of the study is the size of the combined study population
(4,581 subjects with measurements of CIMT and 3,401 with
measurements of CAE) and the extensiveness of the risk factor
data in each cohort. Furthermore, the YFS population comprises
randomly selected healthy individuals from the general popula-
tion. Therefore, the study is free of selection bias. The YFS also
provides a perfect opportunity to follow the development of
subclinical atherosclerosis among healthy young adults because
both CAE and CIMT have been measured from the same
population twice six years apart (2001 and 2007). Although the
Health 2000 survey population also represents a randomly
selected general population, it is not entirely free of selection
bias as the mean age is older (,58 years) and cardiovascular
mortality is likely to affect the study population. Fortunately, we
were able to replicate our findings in the BHS with measurements
of healthy adults of the same age as in the YFS. Due to the fact
that the study populations of the YFS and BHS are relatively
young (mean age ,38 years in both), the result cannot be applied
to older populations. Although the interaction analyses did not
suggest that age would clearly modulate the effect of the genetic
risk score on sub-clinical carotid atherosclerosis, it is possible that,
in older populations, the association would be significant, as
could also be the case for individual SNPs. We withheld from
further age or sex stratifications in the current study population
due to the negative results of the interaction analyses.
Furthermore, such stratifications would have greatly decreased
the power of the study. We also did not analyse the possible
interactions between individual SNPs and risk factors in order to
limit the number of analyses.
While the 24-SNP risk score did not identify subjects with
increased subclinical risk for atherosclerosis, it is still quite possible
that factors associated with pre-symptomatic stages of the disease
could be used for identifying patients more predisposed to severe
endpoints. Thus, in the future more precise methods are required
for studying the mechanism (gene-by-gene interactions and gene-
by-environment interactions) by which these risk factors influence
the development of the disease. Furthermore, although CIMT and
CAE are excellent surrogate phenotypes for studying the
development of subclinical atherosclerosis (the early stages of
intimal thickening), their results should be interpreted with caution
as not all etiological factors are identical in the pathogenesis of
coronary atherosclerosis. Many of the genetic risk factors might
have different effects in different vascular beds and the phenotypes
they promote are diverse as well (from stable manifestations of
coronary artery disease to the most severe forms of acute coronary
syndromes).
In conclusion, most of the studied SNPs should not influence
CAD risk through a mechanism that would also affect the
development of subclinical atherosclerosis measured by CAE or
CIMT in a healthy general population of young adults.
Materials and Methods
Ethics statement
The study was approved by the institutional review board and
the ethics committee of each participating institution (The
Universities of Helsinki, Turku, Tampere, Oulu and Kuopio
and the Institutional Review Board of the Tulane University
Health Sciences Center). Written informed consent was obtained
from each participant in accordance with institutional require-
ments and the principles expressed in the Declaration of Helsinki.
All subjects gave informed consent at each examination, and for
those under 18 years of age, the consent of a parent/guardian was
obtained.
The Cardiovascular Risk in Young Finns Study (YFS)
The YFS is an ongoing multicentre study with a randomly
selected population of Caucasian adults. The study was launched
in 1980 to assess risk factors underlying cardiovascular disease in
children and young adults. The first cross-sectional study was
conducted in 1980 and included 3,596 children and adolescents
aged 3 to 18 years (six equal age cohorts: 3, 6, 9, 12, 15 and 18
years). Five university hospitals in Finland (Turku, Tampere,
Helsinki, Kuopio, and Oulu) are participating in the study. The
risk factor data was collected and CIMT and CAE measured in
the follow-up studies in 2001 (n = 2265) and 2007 (n = 2197). All
subjects gave written informed consent, and the study was
approved by the local ethics committee and the study was
conducted according to the principles expressed in the Declaration
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of Helsinki. The details of this study have been described earlier
more extensively [14].
Clinical Measurements and Questionnaires
Body height, weight, and waist circumference were measured
and body mass index (BMI) was calculated. Blood pressure was
measured thrice with the aid of an automated sphygmomanometer
and the average of the measurements was used in the analyses.
Subjects were also asked to complete questionnaires that included
questions about smoking habits. Those smoking daily were
considered current smokers. Biochemical measurements were
performed following standard protocols (Data S1).
Measurement of subclinical atherosclerosis
In both 2001 and 2007, the ultrasound studies were performed
by trained sonographers following a standardized protocol (high
resolution ultrasound imaging system [Sequoia 512, Acuson]). The
CIMT and CAE measurements were later derived from the
recorded scans by one experienced reader blinded to the subjects’
clinical characteristics. Maximal and mean CIMT of the left
carotid artery (the mean of 4 measurements 10 mm proximal to
the carotid bifurcation) were recorded. CAE values were
determined by selecting the best-quality cardiac cycle from the
clip images and calculating the mean relative diameter change in
carotid diameter (from end-diastole and end-systole) in response to
a concomitant brachial artery blood pressure change. CAE = [(Ds
– Dd)/Dd]/(Ps – Pd), where Dd is diastolic diameter, Ds is systolic
diameter, Ps is systolic blood pressure, and Pd is diastolic blood
pressure. The carotid diameter was measured at least twice (spatial
measurements). The mean of the measurements was used as the
end-diastolic or end-systolic diameter. Concomitant brachial blood
pressure was measured with an automated sphygmomanometer
(Omron M4, Omron Matsusaka Co., Ltd, Japan). To assess intra-
individual reproducibility of ultrasound measurements, 57 subjects
were re-examined three months after the initial visit in 2001 (2.5%
random sample). The between-visit coefficient variation was 6.4%
for CIMT and 16.3% for CAE.
Genotyping and quality control of analyses
Genome-wide SNP data was obtained from 2,442 participants
(1,123 males, 1,319 females) with a custom-built Illumina
BeadChip Human670K including 546,677 SNPs. Genotypes were
called using the Illuminus clustering algorithm [37]. Details of all
experimental methods are described in Data S1.
Replication Cohorts
The Bogalusa Heart Study (BHS): Between 1973 and 2008, 9
cross-sectional surveys of children aged 4–17 years and 10 cross-
sectional surveys of adults aged 18–48 years who had been
previously examined as children were conducted for CVD risk
factor examinations in Bogalusa, Louisiana. This panel design of
repeated cross-sectional examinations has resulted in serial
observations from childhood to adulthood. By linking the 19
surveys, 12,163 individuals have been examined, with 37,317
observations. In the ongoing Longitudinal Aging Study funded by
the NIH and NIA since 2000, 1,202 subjectshave been examined
4–14 times from childhood to adulthood and have DNA available
for GWA genotyping. The genotyping methods and ultrasound
study protocols have been described earlier in detail [38,39].
Health 2000 cohort: The Health 2000 Survey was a large
Finnish cross-sectional health examination survey carried out in
2000–2001. The overall study cohort was a 2-stage stratified
cluster sample (8,028 persons) representing the entire Finnish
population aged 30 years and above (Aromaa A, Koskinen S, Eds.
Health and functional capacity in Finland. Baseline results of the
Health 2000 Health Examination Survey. Helsinki: Publications of
the National Public Health Institute B12/2004; 2004. Available at:
www.ktl.fi/health2000). To study cardiovascular disease risk
factors and diabetes more thoroughly, a supplemental study was
carried out (sample size 1867 and participation rate 82%). The
subjects in the supplemental study were aged 45 years and older,
and the study was conducted in the catchment areas of the five
Finnish University Hospitals. Carotid ultrasound examination was
included in the supplemental study. There were 1,291 subjects
(572 men and 719 women; mean age 58 years; range, 46–76 years)
with available carotid ultrasound data. In the present study, we
used measurements of the mean CIMT and CAE of the common
carotid artery. In the Health 2000 survey, genomic DNA was
extracted from peripheral blood leukocytes and genotyping was
performed by using Taqman SNP Genotyping Assays and the ABI
Prism 7900HT Sequence Detection System (Applied Biosystems,
Foster City, CA, USA). The study protocol was approved by the
Ethics Committee of the National Public Health Institute and
carried out according to the recommendations of the Declaration
of Helsinki. The details of the Health 2000 survey are described in
more detail in Data S1.
Formation of the genetic (CAD) risk score
We calculated a multi-SNP risk score (GRS24SNP/CAD) summa-
rizing the impact of 24 independent CAD- and MIrelated SNPs
for CIMT and CAE. The GRS42SNP/CAD was calculated as
follows: for the i-th SNP in the j-th individual denote xij as the 0/
1/2 coded genotype (for directly genotyped markers) or expected
allele count (real values ranging between 0.0 and 2.0 for imputed
markers). The risk score for participant j is then defined to be:
sj = w1x1j+w2x2j+…+wmxmj, where coefficients w1, w2,…wm are
specified to be the effect sizes, i.e., ORs, for CAD and MI from
reported GWAS [26]. Besides using the weighted risk score, we
also repeated the analyses using a crude risk score without
weighing the allelic effects and including all SNPs in the score.
This procedure did not alter the results in any significant manner
and therefore only the effects of the weighted risk score are
reported. In the BHS cohorts, genotypic information was available
for 23 SNPs in the population of European ancestry and for 19
SNPs in the population of African ancestry. Similar GRSs were
calculated separately for both populations using the genotypic
information of these 23 and 19 SNPs.
Statistical analysis
The endpoints of the YFS were CIMT, CAE, 6-year incidence
of carotid atherosclerosis as well as CIMT and CAE progression
during the follow-up. The 6-year incidence of carotid atheroscle-
rosis was defined as the occurrence of substantial CIMT (age-, sex-
and BMI-adjusted CIMT -value over 90% percentile) or plaque in
2007 in subjects who did not have substantial CIMT or plaque in
2001. Due to the normal distribution of the CIMT and CAE data
in the present study, linear regression was used to investigate the
possible connection between GRS24SNP/CAD and subclinical
atherosclerosis. As it was not clear whether CAD risk score would
have a linear effect on the end-points, the analyses were also
repeated after stratification of study population into four equal
groups (quartiles). All analyses were first performed without
adjustments (Model 1) and secondly adjusting for age, sex and
BMI (Model 2). In the last phase the analyses were adjusted for all
of the risk factors significantly associating with CIMT in a
multivariable regression analysis (Model 3). Covariates were
selected/filtered by a stepwise procedure. In the YFS the following
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covariates were finally used for CIMT: age, waist circumference,
systolic blood pressure, Apolipoprotein A1 and ApolipoproteinB.
For CAE we used systolic blood pressure, age, waist circumfer-
ence, diastolic blood pressure, BMI and glucose. A similar protocol
was also applied when screening for possible associations between
GRSs and CIMT among the study populations of the BHS.
Finally, in the YFS linear regression model adjusted with age, sex
and BMI was employed when screening for as age-group-by-risk
score interaction (study population divided into two equal groups),
a sex-by-risk score interaction and a BMI-by-risk score interaction.
In all study cohorts, analysis of variance (ANOVA) adjusted
with age, sex and BMI was used to screen for associations between
individual SNPs and the endpoints. The associations were also
screened by exploring linear trends using linear regression analysis.
Both methods were employed in order to increase the sensitivity of
the screening. These analyses were not further adjusted because
for most of the polymorphisms, the mechanisms by which they
affect the risk of CAD are unknown. All homozygous carriers of
any given minor genotype were additionally pooled with the
heterozygotes, if the minor genotype represented less than 10% of
the total population.
We have previously shown in the YFS population that it is
possible to predict with good accuracy (using area under the
receiver operating characteristic curve [AUC]), the risk for
extreme CIMT by using multiple SNPs with good predictive
value even though they would not associate statistically signifi-
cantly with CIMT [23]. Therefore, a stratification to high and low
risk groups was employed in order to increase the statistical power
of the variants (e.g. to find positive associations with high
sensitivity). This comparison means comparing two groups from
both ends of the spectrum – with high and low CIMT values. We
used the predefined and reported cut-off of 15% quintiles for
CIMT. A more precise statistical is description available in the
supplementary material.
Study power calculations were performed for the primary study
population (YFS). Based on power analyses conducted for each
SNP, we had at least 80% power at a P-value of 0.05 to detect a
beta value of 0.01 mm for CIMT for most of the SNPs (15/
24,62.5%) and for all SNPs, we obtained a beta value of
0.0155 mm assuming additive genotypic effects. In recessive
models, we had at least 80% power at a P-value of 0.05 to detect
a beta value of 0.075 mm for CIMT for all SNPs. For CAE, we
had at least 80% power at a P-value of 0.05 to detect a beta value
of 0.074%/10 mmHg with most of the SNPs (15/24,62.5%). For
all of the SNPs, we have achieved 80% power at a P-value of 0.05
to detect a beta value of 0.112%/10 mmHg and 0.5370%/
10 mmHg with an additive and a recessive model, respectively. In
the YFS we had 80% power, on a two-sided 0.05 significance level,
to detect an at least 0.017 mm difference in CIMT and a 0.120%/
10 mmHg difference in CAE between individual population
groups when the YFS population was divided into four
categories/quartiles by CAD risk score dosage. Furthermore, we
had an approximately 80% power to detect a change of 0.002 mm
in CIMT and 0.014%/10 mmHg in CAE per one unit change in
allele risk dosage. The statistical power calculation was performed
using QUANTO version 1.2.4.
Finally, a meta-analysis integrating the results of the indepen-
dent study populations (YFS, and BHS and, for some SNPs, also
the Health 2000 survey) was performed by using linear regression
analysis (assuming additive effects for genotypes).
In the YFS population, only 140 subjects were on antihyper-
tensive and 43 on lipid lowering medication. However, as these
factors could possibly confound the analyses, the analyses were
repeated after the exclusion of these subjects. The results remained
unchanged after the adjustments and therefore only the results
before the exclusion are presented.
Most of the genotypes were extrapolated from imputed data and
although the reliability of the imputed data was extremely high we
also repeated the same analyses for the primary endpoints before
pooling the genotypes from the imputed data. Previously each of
the 24 reported SNPs has been associated with CAD at
significance levels exceeding a stringent genome-wide threshold.
In the present study, we considered a p-value of 0.05 statistically
significant provided that the observed effect of the risk allele was in
the same direction as in the original report. Further adjustment
would have weakened the power of the study greatly. All analyses
were performed using SPSS Statistics software (version 18.0; SPSS
Inc.,Chicago, IL, USA) and the meta-analysis using the rmeta-
package (version 2.16) in R software.
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